Retatrutide, the investigational triple receptor agonist developed by Eli Lilly, represents one of the most closely watched advances in obesity and metabolic medicine. By simultaneously targeting GLP-1, GIP, and glucagon receptors, it aims to produce greater reductions in body weight and improvements in glycaemic control than existing single or dual agonists. Phase 2 trial data published in the New England Journal of Medicine have generated considerable interest among clinicians and patients alike. This article explains how retatrutide works, what the current evidence shows, its safety considerations, and its regulatory status in the UK.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly injectable triple receptor agonist developed by Eli Lilly, designed to simultaneously activate GLP-1, GIP, and glucagon receptors to reduce body weight and improve glycaemic control. It has not yet received regulatory approval in the UK or elsewhere.

Retatrutide (development code LY3437943) is an investigational injectable medicine developed by Eli Lilly and Company, currently under clinical evaluation for the treatment of obesity and type 2 diabetes. It is an investigational triple receptor agonist — meaning it is designed to simultaneously activate three distinct hormonal receptors involved in appetite regulation, glucose metabolism, and energy expenditure.

Unlike earlier treatments that target a single receptor pathway, retatrutide engages three complementary hormonal signalling systems. It is administered as a once-weekly subcutaneous injection in clinical trials, a delivery method consistent with other agents in the incretin-based therapy class, such as semaglutide and tirzepatide. It should be noted that the precise dosing regimen and titration schedule are still under investigation and may differ from those used in trials if the medicine is eventually approved.

The triple-receptor mechanism is intended to produce greater and more sustained reductions in body weight and improvements in glycaemic control than single or dual agonists. It has been hypothesised that targeting three complementary pathways simultaneously may help to counteract some of the physiological adaptations — such as compensatory increases in hunger — that can limit the effectiveness of existing treatments, though this remains to be confirmed in clinical studies. It is important to note that retatrutide has not yet received regulatory approval in the UK or elsewhere, and its use remains confined to authorised clinical research settings.

GLP-1, GIP, and Glucagon Receptors: Understanding Triple Agonism

Retatrutide targets three hormonal receptors: GLP-1 (appetite suppression and insulin secretion), GIP (incretin and fat metabolism), and glucagon (energy expenditure and lipolysis). The glucagon component distinguishes it from currently approved agents such as semaglutide and tirzepatide.

To understand retatrutide's potential, it is helpful to consider the three receptor systems it targets:

• GLP-1 (glucagon-like peptide-1) receptor: GLP-1 is an incretin hormone released from the gut after eating. Activation of its receptor stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. GLP-1 receptor agonism is the mechanism shared by established medicines such as semaglutide, which is licensed in the UK as Ozempic® (for type 2 diabetes) and Wegovy® (for weight management).

• GIP (glucose-dependent insulinotropic polypeptide) receptor: GIP is another incretin hormone that enhances insulin secretion and may play a role in fat metabolism and energy storage. Dual GLP-1/GIP agonism is already employed in tirzepatide (Mounjaro®), which is authorised in the UK by the MHRA for both type 2 diabetes and weight management.

• Glucagon receptor: Glucagon is traditionally associated with raising blood glucose by stimulating hepatic glucose production. However, glucagon receptor agonism at carefully balanced levels has been proposed — based on preclinical and early clinical data — to increase energy expenditure, promote fat breakdown (lipolysis), and reduce liver fat content. These effects remain under active investigation in humans, and the evidence base is not yet definitive. This third component is what distinguishes retatrutide from currently approved agents.

By combining all three mechanisms, retatrutide aims to produce a synergistic effect on weight reduction and metabolic health. The glucagon component is thought to enhance thermogenesis — the body's heat-generating metabolic processes — potentially contributing to fat loss beyond what GLP-1 and GIP agonism alone can achieve; however, these mechanistic effects are based on early signals and preclinical data and require confirmation in larger human studies. A key pharmacological challenge in the drug's design is balancing glucagon receptor activity to avoid unwanted increases in hepatic glucose production and net hyperglycaemia, which would counteract the glucose-lowering effects of GLP-1 and GIP agonism.

Clinical Trial Evidence and Weight Loss Outcomes

A Phase 2 randomised controlled trial published in the New England Journal of Medicine (2023) showed approximately 24% mean body weight reduction at the highest dose (12 mg) over 48 weeks. Phase 3 trials are ongoing, and long-term cardiovascular outcome data are not yet available.

The most significant clinical data for retatrutide to date comes from a Phase 2 randomised controlled trial published in The New England Journal of Medicine in 2023. This trial enrolled adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, and evaluated multiple doses of retatrutide against placebo over 48 weeks.

The results were notable:

• Participants receiving the highest dose (12 mg) achieved a mean body weight reduction of approximately 24% from baseline at 48 weeks.

• At lower doses, weight reductions were clinically meaningful, ranging from approximately 8% to 17%.

• Improvements were also observed in cardiometabolic markers, including waist circumference, blood pressure, fasting glucose, and lipid profiles.

• Discontinuation rates due to adverse events were higher at higher doses, primarily driven by gastrointestinal side effects.

These figures have been compared with currently approved agents; however, it is important to note that such comparisons are indirect — the trials involved different populations, study durations, and methodologies, and no head-to-head data are available. For context, semaglutide 2.4 mg (Wegovy®) demonstrated approximately 15% mean weight loss in the STEP 1 trial (NEJM, 2021), while tirzepatide achieved up to approximately 22% in the SURMOUNT-1 trial (NEJM, 2022).

Separate Phase 2 data in people with type 2 diabetes (also published in The New England Journal of Medicine, 2023) showed meaningful reductions in HbA1c alongside significant weight loss, suggesting potential utility across metabolic disease. Long-term durability of weight loss and cardiovascular outcomes data are not yet available from Phase 2 studies.

It is important to contextualise these findings appropriately. Phase 2 trials are designed primarily to assess dose-ranging, safety signals, and preliminary efficacy — they are not powered to detect rare adverse events or confirm long-term cardiovascular outcomes. Phase 3 trials are ongoing, and definitive conclusions about retatrutide's benefit-risk profile await those results.

Potential Side Effects and Safety Considerations

The most common side effects are gastrointestinal symptoms — nausea, vomiting, and diarrhoea — typical of GLP-1 receptor agonism. Class-related risks include pancreatitis, gallbladder disease, and a precautionary warning for patients with a history of medullary thyroid carcinoma or MEN2.

Based on Phase 2 trial data, retatrutide's side effect profile appears broadly consistent with other incretin-based therapies, though the addition of glucagon receptor agonism introduces some distinct considerations. As an investigational medicine, its full safety profile will only become clearer through larger Phase 3 trials and, if approved, post-marketing surveillance.

Commonly reported adverse effects include:

• Gastrointestinal symptoms — nausea, vomiting, diarrhoea, and constipation were the most frequently reported side effects, particularly during dose escalation. These are characteristic of GLP-1 receptor agonism and typically diminish over time, though they led to treatment discontinuation in some participants at higher doses.

• Decreased appetite — while therapeutically desirable, this can occasionally lead to inadequate nutritional intake if not monitored.

• Injection site reactions — generally mild and transient.

Class-related safety considerations relevant to GLP-1-containing therapies include:

• Pancreatitis: Patients should be advised to seek prompt medical attention if they experience severe or persistent abdominal pain, as this may be a symptom of pancreatitis. Treatment should be discontinued if pancreatitis is confirmed.

• Gallbladder disease: Cholelithiasis (gallstones) and cholecystitis have been reported with GLP-1 receptor agonists. Patients should seek medical review if they develop upper abdominal pain, fever, or jaundice.

• Dehydration and acute kidney injury: Gastrointestinal side effects can lead to dehydration. Patients should be advised to maintain adequate fluid intake, particularly during dose escalation. Caution is warranted in those with pre-existing renal impairment.

• Increased heart rate: A modest increase in resting heart rate has been observed with GLP-1 receptor agonists and should be monitored.

• Hypoglycaemia: When used in combination with insulin or sulfonylureas, there is an increased risk of hypoglycaemia. Dose adjustments of concomitant glucose-lowering medicines may be required.

• Diabetic retinopathy: Rapid improvement in glycaemic control has been associated with worsening of diabetic retinopathy in some patients. Appropriate ophthalmological monitoring is advisable in those with pre-existing retinopathy.

• Thyroid C-cell tumours: Rodent studies with GLP-1 receptor agonists have shown C-cell tumours at clinically irrelevant exposures; the relevance to humans is uncertain. As a precaution, patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should discuss this with their clinician before considering any GLP-1-containing therapy. Patients should seek medical review if they notice a neck mass, hoarseness, or difficulty swallowing.

• Pregnancy and breastfeeding: GLP-1-containing therapies are not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception. Retatrutide has not been studied in these populations.

• Severe gastrointestinal disease: Caution is advised in patients with conditions such as gastroparesis or severe inflammatory bowel disease, as GLP-1 receptor agonism slows gastric emptying.

• Use in children: Retatrutide has not been studied in children or adolescents.

The glucagon receptor component warrants particular attention regarding long-term hepatic and metabolic effects, which require further dedicated investigation.

Patients and healthcare professionals are encouraged to report any suspected adverse reactions via the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk), which supports ongoing safety monitoring of medicines and vaccines in the UK.

Current Regulatory Status and What to Expect from the MHRA

Retatrutide is not approved by the MHRA, EMA, or FDA and remains available only within authorised clinical trials. Phase 3 TRIUMPH programme trials are underway, but no regulatory submission timeline has been confirmed.

As of the time of writing, retatrutide has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, nor by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA). It remains an investigational medicinal product, available only within the context of authorised clinical trials.

Eli Lilly has initiated Phase 3 clinical trials — the TRIUMPH programme — evaluating retatrutide across a range of populations, including adults with obesity, type 2 diabetes, and obesity-related cardiovascular disease. These trials are expected to generate the robust, large-scale efficacy and safety data required to support a regulatory submission. No official timeline for a regulatory submission or potential approval has been confirmed.

In the UK, the MHRA operates an independent post-Brexit regulatory framework. Should Phase 3 data prove favourable, a regulatory submission could follow, though the timing remains uncertain and no predictions should be drawn from the approval timelines of other medicine classes. NHS funding for any approved medicine would be subject to a separate NICE technology appraisal process.

For patients and healthcare professionals interested in access prior to potential approval, participation in MHRA-authorised clinical trials remains the appropriate route. The NIHR Be Part of Research platform (bepartofresearch.nihr.ac.uk) provides information on available trials in the UK. Patients should exercise caution regarding unregulated or unlicensed sources offering investigational compounds outside of clinical trial settings, as these carry significant safety risks.

In the meantime, clinicians managing patients with obesity or type 2 diabetes should continue to follow current NICE guidance, including CG189 (Obesity: identification, assessment and management), NG28 (Type 2 diabetes in adults), and the relevant NICE technology appraisals for currently approved weight management medicines, including semaglutide 2.4 mg (Wegovy®). Retatrutide represents a promising area of ongoing research in metabolic medicine, but evidence-based, regulated care with currently approved therapies remains the cornerstone of safe clinical practice.

Frequently Asked Questions